Implications of 2023 ACR/EULAR classification criteria for antiphospholipid syndrome and current diagnostic and therapeutic insights: A Delphi consensus
Open Access
- 14 February 2026
- journal article
- review article
- Published by Elsevier in The American Journal of Medicine
- Vol. 139 (6) , 708-717.e5
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- The 2023 ACR/EULAR antiphospholipid syndrome classification criteria identify patients at high risk of complicationsClinical Rheumatology, 2024
- The 2023 ACR/EULAR Antiphospholipid Syndrome Classification CriteriaArthritis & Rheumatology, 2023
- Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndromeSeminars in Immunopathology, 2022
- DOAC‐Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samplesResearch and Practice in Thrombosis and Haemostasis, 2021
- Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and RepositoryArthritis Care & Research, 2020
- The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective studyAutoimmunity Reviews, 2020
- Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy OutcomesArthritis & Rheumatology, 2016
- Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negativeImmunologic Research, 2013
- Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patientsArthritis & Rheumatism, 2002
- International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshopArthritis & Rheumatism, 1999